Abstract 102P
Background
Acute lymphoblastic leukemia is the most common type of cancer among children. Around 20% of patients relapse after remission. Minimal residual disease (MRD) is used as a predictor of relapse. MDR is measured by flow cytometry in bone marrow samples. MicroRNAs are small non-coding RNAs that regulate gene expression, acting as oncogenic or tumor suppressor biomolecules. MicroRNAs are secreted in various biofluids, including urine or saliva, at levels that reflect the homeostatic state of an individual. These secreted microRNAs might be useful as non-invasive biomarkers of MRD and treatment follow up in leukemia. This study aims to identify and evaluate the usefulness of urinary and salivary microRNAs as biomarkers of MRD in children diagnosed with acute lymphoblastic leukemia.
Methods
Saliva and urine samples, from high (MRD≥10) and standard intermediate (MDR<10) risk of relapse children, were collected on day 15 of chemotherapy. MicroRNAs were extracted using a commercial kit and sequenced to identify differences in secretion patterns. Differential expression analysis was carried out using the DeSeq2 algorithm.
Results
The mean MRD on day 15 was 52.23 % ± 38.42 and 1.03 % ± 0.53 in the high risk and standard intermediate risk children, respectively. Twenty-three microRNAs were differentially secreted (adjusted p-value < 0.01 and log 2 fold change > 1) between the high risk and standard intermediate children in saliva (12 upregulated and 11 downregulated). In contrast, only 3 sequences were differentially secreted (all downregulated) in urine samples. The miR-1246 and miR-3976 showed the highest increase (log 2 fold change = 7.53) and decrease (log 2 fold change = -5.52), respectively, in saliva samples. In urine miR-4783-5p showed the highest decrease (log 2 fold change = -3.15). However, these results need to be validated using PCR techniques.
Conclusions
In conclusion, miR-1246, miR-3976 and miR-4783-5p show promising utility as MRD biomarkers for monitoring MRD and treatment follow up in children diagnosed with ALL. With the additional advantage that microRNAs are more stable than other molecular markers and urine and saliva samples are non-invasive and easy to collect.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
FONDECYT-CONCYTEC (Grant Contract Number 165-2020-FONDECYT).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract